Implementación del inmunoanalizador diagnóstico totalmente automatizado cobas e411 en el laboratorio bioanalítico:...

This study assessed the automated cobas e411 immunoanalyzer as a high-efficiency alternative to manual ELISA for pharmacokinetic and pharmacodynamic analyses. Key objectives included reducing manual resource burdens and minimizing analyst-dependent variability while achieving analytical performance comparable or superior to established ELISA standards.

To achieve GLP and FDA 21 CFR Part 11 and 58 compliance, a dedicated "Elecsys system", comprising the off-the-shelf cobas e411 platform and an in-house developed software package (CoLiBri) for instrument control and LIMS connection was subjected to Computerized System Validation (CSV). The Elecsys system's analytical performance was compared directly to ELISA. Robustness was further assessed through clinical sample analysis and free analyte quantification in biological matrices.

The cobas e411 demonstrated comparable sensitivity and precision to ELISA while offering a significantly wider dynamic range due to electrochemiluminescence readout. Automation minimized human error and enabled high-throughput singlicate analysis, a capability unattainable with manual methods. Validation of numerous non-clinical and clinical assays and routine sample analyses confirmed platform's efficiency and ability to provide rapid turnaround for bioanalysis.

The Elecsys system is a robust, GLP-compliant platform that streamlines bioanalytical workflows. By automating labor-intensive steps, it significantly enhances data quality and efficiency compared to traditional manual ligand-binding assays.